Low dose quadruple therapy for two weeks as "second line" treatment for cure of H-pylori infection after failure of standard triple therapy

被引：0
|
作者：
Pieramico, O
Zanetti, MV
机构：
[1] Gen Hosp, Div Internal Med, Merano, Italy
[2] Gen Hosp, Microbiol Lab, Merano, Italy
来源：
GUT | 2002年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1531
引用
收藏
页码：A98 / A98
页数：1
相关论文
共 50 条
  • [1] Predictors of failure of H-pylori infection after the standard "Maastricht triple therapy"
    Perri, F
    Villani, MR
    Festa, V
    Quitadamo, M
    Andriulli, A
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A591 - A591
  • [2] Levofloxacin based triple therapy as second-line treatment for H. pylori infection after failure of standard triple therapy.
    Festa, V
    Perri, F
    Boschetto, S
    Giovannone, M
    Tosoni, M
    Andriulli, A
    Barberani, F
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A587 - A587
  • [3] SECOND- LINE RESCUE TRIPLE THERAPY WITH LEVOFLOXACIN AFTER FAILURE OF NON- BISMUTH QUADRUPLE " SEQUENTIAL" OR " CONCOMITANT" TREATMENT TO ERADICATE H-PYLORI INFECTION
    Gisbert, J. P.
    Molina-Infante, J.
    Marin, A. C.
    Vinagre, G.
    Barrio, J.
    McNicholl, A. G.
    [J]. HELICOBACTER, 2013, 18 : 128 - 128
  • [4] Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple "Sequential" or "Concomitant" Treatment to Eradicate H-pylori Infection
    Gisbert, Javier P.
    Molina-Infante, Javier
    Marin, Alicia C.
    Rodriguez, Gema Vinagre
    Barrio, Jesus
    McNicholl, Adrian G.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S394 - S394
  • [5] Treatment with quadruple therapy after triple therapy failure in patients infected with H-pylori resistant strains.
    Pieramico, O
    Zanetti, MV
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A282 - A282
  • [6] Sequential Levofloxacin modified therapy is superior to quadruple therapy but equivalent to standard Levofloxacin based second line treatment in patients with H-pylori infection
    Franceschi, F.
    Finizio, R.
    Campanale, M.
    Barbaro, F.
    Gigante, G.
    Cesario, V.
    Tortora, A.
    Calcinaro, S.
    Marsiliani, D.
    Carroccia, A.
    Silveri, N. Gentiloni
    Curro, D.
    Cammarota, G.
    Gasbarrini, G.
    Gasbarrini, A.
    [J]. HELICOBACTER, 2010, 15 (04) : 314 - 315
  • [7] Dual therapy with high-dose of rabeprazole and amoxicilline versus triple therapy with rabeprazole, amoxicilline and metronidazole as the second line therapy for the cure of H-pylori infection.
    Shirai, N
    Furuta, T
    Sugimoto, M
    Nakamura, A
    Kajimura, M
    Takeshita, A
    Maekawa, M
    Ohashi, K
    Ishizaki, T
    Hishida, A
    [J]. GASTROENTEROLOGY, 2005, 128 (04) : A430 - A430
  • [8] Eradication rate of Bismuth-containing quadruple therapy as a second-line treatment for H-pylori infection
    Jee, S. R.
    Lee, S. H.
    Jung, E. U.
    Ok, K. S.
    Kim, J. H.
    Choi, J. S.
    Lee, Y. J.
    Seol, S. Y.
    [J]. HELICOBACTER, 2010, 15 (04) : 345 - 345
  • [9] H. pylori Second-Line Rescue Therapy With Levofloxacin and Bismuth After Failure of Standard Triple or Non-Bismuth Quadruple Treatment
    Gisbert, Javier P.
    Romano, Marco
    Gravina, Antonietta G.
    Munoz, Pablo Solis
    Bermejo, Fernando
    Molina-Infante, Javier
    Castro-Fernandez, Manuel
    Ortuno, Juan A.
    Lucendo, Alfredo J.
    Herranz-Bachiller, MTeresa
    Modolell, Ines
    Corzo, Francisco Jose del Castillo
    Gomez-Camarero, Judith
    Barrio, Jesus
    Velayos, Benito
    Rodriguez, Blas Jose Gomez
    Dominguez-Jimenez, Jose Luis
    Algaba, Alicia
    Pabon, Manuel
    Angueira, Teresa
    Salazar, Luis Fernandez
    Marin, Alicia C.
    McNicholl, Adrian G.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S416 - S416
  • [10] Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy
    Watanabe, Y
    Aoyama, N
    Shirasaka, D
    Maekawa, S
    Kuroda, K
    Miki, I
    Kachi, M
    Fukuda, M
    Wambura, C
    Tamura, T
    Kasuga, M
    [J]. DIGESTIVE AND LIVER DISEASE, 2003, 35 (10) : 711 - 715
12345